The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Group II Metabotropic Glutamate Receptors Modulate Extracellular Glutamate in the Nucleus Accumbens
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors
Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883
Chavis, P., Shinozaki, H., Bockaert, J., & Fagni, L. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-11-07067.1994 · Cited by 130
Cited by
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
Moffett, J. R., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,405
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“In addition, G-protein coupled glutamate receptors, the metabotropic receptors, modulate glutamatergic neurotransmission; for instance, presynaptic mGluR3 receptors inhibit the release of glutamate (Xi et al., 2002).”
BackgroundMcFarland, K., Lapish, C. C., & Kalivas, P. W. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03531.2003 · Cited by 885
Self-citationThe Neuroscience of Drug Reward and Addiction
Volkow, N. D., Michaelides, M., & Baler, R. (2019) · Physiological Reviews · doi:10.1152/physrev.00014.2018 · Cited by 863
The SLC3 and SLC7 families of amino acid transporters
Fotiadis, D., Kanai, Y., & Palacín, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.007 · Cited by 680
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
“…infusion of the mGluR2/3 antagonist LY341495 (2-[(1S,2S)-2-carboxycyclopropyl]-3-(9H-xanthen-9-yl)-Dalanine) increased baseline levels of glutamate (Xi et al., 2002; Moussawi and Kalivas, 2010), whereas the same antagonist caused an increase in evoked EPSC amplitude (Moussawi et al., 2011; Kupchik…”
BackgroundSelf-citationThe Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate
Baker, D. A., Xi, Z.-X., Shen, H., Swanson, C. J., & Kalivas, P. W. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09134.2002 · Cited by 584
Self-citationContext-induced relapse to drug seeking: a review
Crombag, H. S., Bossert, J. M., Koya, E., & Shaham, Y. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0090 · Cited by 495
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Monoamine transporters and psychostimulant addiction
Howell, L. L., & Kimmel, H. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.003 · Cited by 255
Repeated N-Acetylcysteine Administration Alters Plasticity-Dependent Effects of Cocaine
Madayag, A., Lobner, D., Kau, K. S., Mantsch, J. R., Abdulhameed, O., Hearing, M., Grier, M. D., & Baker, D. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-07.2007 · Cited by 225
Self-citationBridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205
“…of highaffinity group II/III metabotropic glutamate receptors, which are negatively coupled to synaptic release of glutamate or other neurotransmitters such as dopamine (Baskys and Malenka, 1991; Cochilla and Alford, 1998; Hu et al., 1999b; Baker et al., 2002; Xi et al., 2002a; Moran et al., 2005).”
BackgroundSelf-citationLiechti, M. E., Lhuillier, L., Kaupmann, K., & Markou, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-07.2007 · Cited by 193
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.011 · Cited by 174
“Toward this goal, recent clinical evidence has shown that a single, low dose of ketamine produces rapid and long lasting antidepressant effects in treatment resistant patients (Berman et al., 2000; Price et al., 2009; Zarate et al., 2006).”
mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169
“To evaluate whether mGluR2/3 blockade increases synaptic proteins, we measured levels of synaptic proteins in the PFC 24 hrs after a single dose of LY341495.”
BackgroundInfluentialMorishima, Y., Miyakawa, T., Furuyashiki, T., Tanaka, Y., Mizuma, H., & Nakanishi, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500914102 · Cited by 148
Melendez, R. I., Lee Gregory, M., Bardo, M. T., & Kalivas, P. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300507 · Cited by 104
“Tissue homogenization, electrophoresis and immunoblotting were conducted as described by Xi et al (2002b).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Xi, Z.-X., Baker, D. A., Shen, H., Carson, D. S., & Kalivas, P. W.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 300
- Issue
- 1
- Pages
- 162-171
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2044745774
- Cited by
- 212
- References
- 2
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.